TR201903223T4 - Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı. - Google Patents

Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı. Download PDF

Info

Publication number
TR201903223T4
TR201903223T4 TR2019/03223T TR201903223T TR201903223T4 TR 201903223 T4 TR201903223 T4 TR 201903223T4 TR 2019/03223 T TR2019/03223 T TR 2019/03223T TR 201903223 T TR201903223 T TR 201903223T TR 201903223 T4 TR201903223 T4 TR 201903223T4
Authority
TR
Turkey
Prior art keywords
tuberculosis
vaccine
prevent reactivation
reactivation
muberculosis
Prior art date
Application number
TR2019/03223T
Other languages
English (en)
Inventor
Dietrich Jes
Andersen Peter
Vingsbo Lundberg Carina
Thi Kim Than Hoang Truc
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Publication of TR201903223T4 publication Critical patent/TR201903223T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Mevcut buluş, tüberküloz kompleksi mikroorganizmalarının (Mycobacterium tuberculosis., M.bovis, M.africanum) türlerinden kaynaklanan latent tüberküloz enfeksiyonunun reaktivasyonunu önlemek üzere latent olarak enfekte bireylere uygulanabilen bir aşıyı veya immünojenik bileşimi açıklar, Buluş, enfeksiyonun farklı aşamalarında temel olarak ifade edilen birçok M. muberculosis derive protein ve protein fragmanına bağlıdır. Buluş, bu polipeptidler, bunların immünolojik olarak aktif fragmanları ve aşılar gibi immünolojik bileşimlere yönelik bunları kodlayan genlerin kullanımı ile ilgilidir.
TR2019/03223T 2009-04-24 2010-04-23 Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı. TR201903223T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200900539 2009-04-24

Publications (1)

Publication Number Publication Date
TR201903223T4 true TR201903223T4 (tr) 2019-03-21

Family

ID=43010694

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/03223T TR201903223T4 (tr) 2009-04-24 2010-04-23 Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı.

Country Status (17)

Country Link
US (2) US9074001B2 (tr)
EP (1) EP2421557B1 (tr)
JP (2) JP5839361B2 (tr)
KR (2) KR20170072366A (tr)
CN (2) CN104107425B (tr)
AU (1) AU2010238943B9 (tr)
BR (1) BRPI1006452A2 (tr)
CA (1) CA2759583C (tr)
DK (1) DK2421557T3 (tr)
ES (1) ES2714383T3 (tr)
HK (2) HK1204549A1 (tr)
IL (1) IL215591A (tr)
MX (2) MX370744B (tr)
PL (1) PL2421557T3 (tr)
TR (1) TR201903223T4 (tr)
WO (1) WO2010121618A1 (tr)
ZA (1) ZA201108564B (tr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1877426T3 (da) 2005-04-29 2012-05-14 Glaxosmithkline Biolog Sa Fremgangsmåde til forebyggelse eller behandling af M Tuberculosis-infektion.
GB0618127D0 (en) * 2006-09-14 2006-10-25 Isis Innovation Biomarker
MX2011000982A (es) 2008-07-25 2011-03-02 Glaxosmithkline Biolog Sa La proteina de tuberculosis rv2386c, composiciones y usos de la misma.
BRPI0916705A2 (pt) 2008-07-25 2015-11-10 Glaxo Group Ltd polipeptídeo isolado, polinucleotídeo isolado, composição farmacêutica, composição imunogênica, método para tratamento ou prevenção de tuberculose, e, usos de um polipeptídeo, e de um polinucleotídeo.
LT2315773T (lt) * 2008-07-25 2016-11-10 Glaxosmithkline Biologicals S.A. Polipeptidai, polinukleotidai ir kompozicijos, skirti naudoti latentinės tuberkuliozės gydymui
GB0906215D0 (en) 2009-04-09 2009-05-20 Lalvani Ajit Diagnostic test
HUE031184T2 (en) 2010-01-27 2017-06-28 Glaxosmithkline Biologicals Sa Modified tuberculosis antigens
BR112013017267B1 (pt) 2011-01-04 2021-06-22 Archivel Farma, Sl Formulação de lipossomas, suspensão e composição farmacêutica
DK2802345T3 (en) 2012-01-12 2018-04-30 Archivel Farma Sl MTB-C-VACCINE AGAINST ALLERGIC REACTIONS
WO2014063704A2 (en) * 2012-10-23 2014-05-01 Statens Serum Institut M. tuberculosis vaccines
JP2016516075A (ja) * 2013-03-15 2016-06-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 結核の予防または治療用の合成免疫原
LT3084442T (lt) * 2013-12-16 2021-07-12 Statens Serum Institut Diagnostiniai reagentai, skirti pagerintai in vivo arba in vito ląstelių medijuojamai imunologinei tuberkuliozės diagnozei
EP3092000A1 (en) * 2014-01-09 2016-11-16 Transgene SA Fusion of heterooligomeric mycobacterial antigens
JP2017513860A (ja) * 2014-04-24 2017-06-01 スタテンス セールム インスティトゥート 新規結核菌（ｍ．ｔｕｂｅｒｃｕｌｏｓｉｓ）ワクチン
CN104151433A (zh) * 2014-08-11 2014-11-19 兰州大学 一种结核分枝杆菌融合蛋白及其制备方法和应用
CN104225591A (zh) * 2014-09-15 2014-12-24 兰州大学 一种免疫佐剂及含有该免疫佐剂的疫苗
JP2019521095A (ja) * 2016-05-21 2019-07-25 インフェクシャス ディズィーズ リサーチ インスティチュート 二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
WO2019210282A2 (en) * 2018-04-26 2019-10-31 Children's National Medical Center Mycobacterial antigen compositions and methods of use
CN110423279B (zh) * 2019-06-20 2021-07-27 扩增生物科技(北京)有限公司 结核分枝杆菌重组融合蛋白eecc及其制备方法和应用
KR102577332B1 (ko) * 2021-12-29 2023-09-11 재단법인 오송첨단의료산업진흥재단 항원성 및 안정성이 개선된 항원을 포함하는 잠복결핵 진단용 조성물
CN117777259B (zh) * 2024-02-23 2024-06-07 上海科新生物技术股份有限公司 检测结核感染的抗原组合物、试剂盒及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US5955077A (en) * 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
CN1105236A (zh) * 1993-11-13 1995-07-19 丛繁滋 肺结核防传播及治疗用气雾剂及其制备方法
CN1051234C (zh) * 1994-04-15 2000-04-12 焦安国 一种治疗结核病的药物
DK0832093T3 (da) 1995-06-07 2007-01-08 Sanofi Pasteur Inc Udtrykkelse af lipoproteiner
US6338852B1 (en) * 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
WO2001004151A2 (en) 1999-07-13 2001-01-18 Statens Serum Institut TUBERCULOSIS VACCINE AND DIAGNOSTICS BASED ON THE MYCOBACTERIUM TUBERCULOSIS esat-6 GENE FAMILY
WO2001079274A2 (en) 2000-04-19 2001-10-25 Statens Serum Institut Tuberculosis antigens and methods of use thereof
GB0030368D0 (en) 2000-12-13 2001-01-24 Inst Of Molecul & Cell Biology Dormancy-induced mycobacterium proteins
WO2002054072A2 (en) * 2001-01-08 2002-07-11 Isis Innovation Limited Assay to determine efficacy of treatment for mycobacterial infection
PT1350839E (pt) * 2002-04-05 2010-08-12 Pasteur Institut Identificação de regiões rd1 e rd5 associadas a virulência que permitam o desenvolvimento de vacinas melhoradas de m. bovis bcg e m. microti
EP1523331B1 (en) 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
WO2004067718A2 (en) 2003-01-24 2004-08-12 Emory University Necrosis-deficient mutants of tuberculosis bacteria
EP1781313A4 (en) * 2004-06-17 2009-08-26 Beckman Coulter Inc MYCOBACTERIUM TUBERCULOSIS EPITOPES AND METHODS OF USE
CA2586620C (en) * 2004-11-16 2014-06-03 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
EA012436B1 (ru) 2005-01-05 2009-10-30 Айсис Инновейшн Лимитед Композиции для иммунизации против микобактерий
DK1877426T3 (da) 2005-04-29 2012-05-14 Glaxosmithkline Biolog Sa Fremgangsmåde til forebyggelse eller behandling af M Tuberculosis-infektion.
CA2612900C (en) * 2005-06-23 2016-08-09 Claus Aagaard Improved tuberculosis vaccines
EP2040745B1 (en) * 2006-06-28 2012-12-05 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
LT2315773T (lt) 2008-07-25 2016-11-10 Glaxosmithkline Biologicals S.A. Polipeptidai, polinukleotidai ir kompozicijos, skirti naudoti latentinės tuberkuliozės gydymui

Also Published As

Publication number Publication date
MX370744B (es) 2019-12-20
ZA201108564B (en) 2018-11-28
JP2015199771A (ja) 2015-11-12
CN104107425B (zh) 2018-07-17
JP5839361B2 (ja) 2016-01-06
JP2012524733A (ja) 2012-10-18
AU2010238943A9 (en) 2015-10-15
IL215591A0 (en) 2011-12-29
CA2759583A1 (en) 2010-10-28
ES2714383T3 (es) 2019-05-28
US9074001B2 (en) 2015-07-07
DK2421557T3 (en) 2019-03-25
WO2010121618A1 (en) 2010-10-28
IL215591A (en) 2016-03-31
MX2011011186A (es) 2012-02-13
EP2421557B1 (en) 2018-12-05
CN102413837B (zh) 2015-11-25
US10519202B2 (en) 2019-12-31
EP2421557A1 (en) 2012-02-29
BRPI1006452A2 (pt) 2016-12-27
AU2010238943A1 (en) 2011-11-03
AU2010238943B9 (en) 2015-10-15
AU2010238943B2 (en) 2015-09-17
US20150093407A1 (en) 2015-04-02
HK1204549A1 (en) 2015-11-27
JP6215260B2 (ja) 2017-10-18
CN102413837A (zh) 2012-04-11
KR20170072366A (ko) 2017-06-26
CA2759583C (en) 2020-06-16
CN104107425A (zh) 2014-10-22
HK1166018A1 (zh) 2012-10-19
US20120039925A1 (en) 2012-02-16
EP2421557A4 (en) 2013-03-13
KR20120014176A (ko) 2012-02-16
PL2421557T3 (pl) 2019-07-31

Similar Documents

Publication Publication Date Title
TR201903223T4 (tr) Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı.
PH12014502250A1 (en) Mycoplasma hyopneumoniae vaccine
WO2009072767A3 (en) A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant
TR201802380T4 (tr) Benzonaftiridin içeren aşılar.
MX340830B (es) Vacuna neumococica y usos de la misma.
MX355366B (es) Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion.
BR112013009164A2 (pt) capsídeo de norovírus e proteína vp6 de rotavírus para uso como vacina combinada.
EA201500054A1 (ru) Аттенуированные вакцины против streptococcus suis и способы их получения и применения
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
BRPI1007721B1 (pt) composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66
EA201290956A1 (ru) Вакцина против вич
AR080111A1 (es) Metodos y composiciones de inmunizacion
CO6670521A2 (es) Vacuna y m´todos para reducir una infección por campylobacter
MX2016001695A (es) Composiciones inmunogenas de combinacion.
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
WO2011082422A3 (en) Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications
MX2018012270A (es) Novedosas formulaciones de vacuna neumococica.
TR201911128T4 (tr) Neısserıa menıngıtıdıs fhbp varyantı ve bunun aşılamaya yönelik kullanımı.
GB2515222A (en) Use of flagellin as a vaccine
WO2013084070A3 (en) Salmonella vaccine proteins
WO2011112906A3 (en) Novel immunogens and methods for discovery and screening thereof
WO2010080188A3 (en) Epitope targeted anthrax vaccine
WO2013173256A3 (en) New and improved influenza vaccines
MX2015005112A (es) Composicion inmunogenica contra la aeromonas hydrophila.
MX2014009022A (es) Virus de influenza c y vacuna.